PLUS1
193.74
-23.03 (-10.62%)
-23.03 (-10.62%)
Upgrade to Real-Time
Afterhours (Closed)
Low
192.88
High
306.08
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -23.03 | -10.62% | 193.74 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 194.04 | 192.885 | 200.05 | 193.02 | 216.77 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 193.60 | 194.04 | 0.44 | - | 3 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 157,340 | 13,725,775 | $ 195.53 | $ 2,683,852,669 | 1,554,637 | 192.88 - 306.08 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:23 | 38 | $ 193.84 | USD |
Vertex Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 50.15B | 258.87M | 258.72M | $ 6.21B | $ 2.67B | 10.31 | 20.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 14.29k | 0.90% |
Vertex Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 211.68 | 217.26 | 192.88 | 212.35 | 1,989,299 | -17.94 | -8.48% |
| 1 Month | 215.10 | 218.97 | 192.88 | 211.72 | 1,641,620 | -21.36 | -9.93% |
| 3 Months | 214.44 | 222.78 | 192.88 | 214.09 | 1,622,209 | -20.70 | -9.65% |
| 6 Months | 224.10 | 242.99 | 192.88 | 218.25 | 1,815,652 | -30.36 | -13.55% |
| 1 Year | 275.56 | 306.08 | 192.88 | 233.32 | 1,759,230 | -81.82 | -29.69% |
| 3 Years | 150.67 | 306.08 | 145.37 | 213.04 | 1,521,650 | 43.07 | 28.59% |
| 5 Years | 91.24 | 306.08 | 71.46 | 176.18 | 1,562,377 | 102.50 | 112.34% |
Vertex Pharmaceuticals Description
| Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex's pipeline includes gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. Vertex also has an expanding research pipeline focused on inflammatory diseases, non-opioid treatments for pain, and genetic and cell therapies for type 1 diabetes and rare diseases. |
